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not reﬂect the actual level of utilization and need to be
completed with alternative methods of data collection.
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REIMBURSEMENT PROCEDURE
Umbach I, Quaetaert M,Vannecke C, Dewitte M,
Ravelingien I,Verpooten G, Tomas M
NIHISB, Brussels, Belgium
OBJECTIVES: Belgium has implemented since January
2002 a new reimbursement structure—the Commission
for the Reimbursement of Medicines (CRM). One of the
objectives is to improve time taken between the granting
of a marketing authorisation and pricing/reimbursement
decisions in full consistency with the European Commu-
nity legislation. METHODS: The CRM is responsible for
both clinical and economic evaluation of the submissions.
The decision relating to the admission of a specialty to
the list of reimbursed products is taken after evaluation
of several criteria: therapeutic value, price and basis for
reimbursement, therapeutic and social needs, budget
impact and cost-effectiveness. With regard to the thera-
peutic value, three classes have been deﬁned: class 1)
demonstrated added value; class 2) no added value; and
class 3) generic drugs. For an independent evaluation of
the dossiers the NIHISB has appointed a team of internal
experts. They provide evaluation reports within 60 days
and a reimburserment proposal within 150 days, to be
endorsed by the CRM. Guidelines have been developed
to assist applicants in preparing their submissions.
RESULTS: From January 1st to June 1st, 2002, 219
dossiers have been submitted to the CRM. Seventy-one
evaluation reports were issued during the same period
and timeline compliance was >90%. CONCLUSIONS:
After ﬁve months of CRM functioning, the timelines are
respected and a large majority of the evaluation reports
produced by the internal experts were endorsed. The
main challenges for the future will be to keep trans-
parency and consistency in the decisions taken, to respect
the short deadlines, to maintain the independence of mind
of the experts, and to continue to evaluate sequentially
the scientiﬁc and ﬁnancial aspects in the decision making
process.
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OBJECTIVES: Although mainly ﬁnanced by public
resources, Belgian patients are in most cases bound to pay
a contribution for medical acts and services described in
a very precise nomenclature. In order to lower the burden
of health care costs, the minister of social affairs recently
restricted this patients’ contribution to a maximum
(regarding the nomenclature and lump sum fees), accord-
ing to the ﬁnancial resources of the beneﬁciary. The goal
of this study is to detect elements that force the level out-
of-pocket payment up so that government actions can
take these results into account. METHODS: A represen-
tative sample of 30 acute hospitals (277.521 inpatient
stays) related to data on utilisation of resources and data
concerning the pathology, was withdrawn from national
databank (1996). Using descriptive statistics the patients’
contributions were mapped. Patients with high personal
contributions were selected and analysed. RESULTS:
On average 17% of the total invoice for a hospital stay
is paid by the patients’ own resources (€198,79). This
amount consists of lump sum fees (60,1%), either paid
per admission (medical imaging, technical procedures,
etc.) or depending on the length of stay, not reimbursed
drugs (14,4%), medical acts and services as described in
the nomenclature (11,3%), supplements for medical
devices (7,4%), various costs (6,7%) and clinical biology
(0,1%). Certain patients groups, depending on the
pathology, bear a signiﬁcant larger personal contribution.
CONCLUSIONS: The “maximum invoice” does not fully
cover all out-of-pocket payments. These ﬁndings may
lead to further discussion considering criteria for the
“maximum invoice”.
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OBJECTIVE: According to a law recently enacted in
Germany “aut idem” is an imprint on the prescription
obliging the pharmacist to give the patient a drug out of
a group of its cheapest generic versions, unless the physi-
cian excludes this by marking “nec aut idem” on the 
prescription. In view of the Statuary Health Insurance
spendings on pharmaceuticals the Ministry of Health thus
intends to achieve savings of €250 million p. a. but doubts
are manifold. To analyse the efﬁciency of “aut idem” a
model calculation was made for epilepsy treatment.
METHOD: In a decision tree model the costs of “aut
idem” versus “nec aut idem” prescription of Carba-
mazepin were calculated. “Nec aut idem” brings no
change for the patient whereas “aut idem” effects a drug
switch with multiple risks for the patients. On the basis
of up-to-date literature and ofﬁcial data sources assump-
tions were made on the reduction of drug efﬁcacy due to
modiﬁed bioavailability, a risk for 15% of the patients,
with additional ﬁts leading to an increase in treatment
expenses of which only the costs for the patients’ 
social health insurance were taken into consideration.
RESULTS: The What-if-analysis gives proof that in the
ratio of €114,93 to €56,18 “aut idem” is more expensive
